SOPHiA GENETICS (SOPH) Gains from Sales and Divestitures (2021 - 2023)
SOPHiA GENETICS's (SOPH) quarterly Gains from Sales and Divestitures came in at $28000.0 in Q4 2023, little changed quarter-over-quarter from $28000.0 in Q3 2023.
SOPHiA GENETICS (SOPH) Gains from Sales and Divestitures (2021 - 2023) Analysis & Trends
SOPHiA GENETICS has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $28000.0 for Q4 2023.
- Gains from Sales and Divestitures for Q4 2023 came in at $28000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $28000.0 (changed N/A YoY), and the FY2023 annual result was $28000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $28000.0 for Q4 2023 at SOPHiA GENETICS, roughly flat from $28000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $28000.0 in Q3 2023 to a low of $22000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Veeva Systems | 24.83 Bn | 17.52 Bn | 662.02 Mn |
| 2 | BrightSpring Health Services | 13.57 Bn | 12.69 Bn | 482.22 Mn |
| 3 | Healthequity | 7.20 Bn | 6.93 Bn | 256.31 Mn |
| 4 | Hinge Health | 5.42 Bn | 5.11 Bn | 154.23 Mn |
| 5 | 10x Genomics | 4.46 Bn | 3.92 Bn | 106.18 Mn |
| 6 | Doximity | 3.81 Bn | 3.06 Bn | 125.97 Mn |
| 7 | Waystar Holding | 3.52 Bn | 3.36 Bn | 268.04 Mn |
| 8 | Privia Health | 2.94 Bn | 2.57 Bn | 595.71 Mn |
| 9 | Omnicell | 1.76 Bn | 1.59 Bn | 140.36 Mn |
| 10 | SOPHiA GENETICS | 26.19 Mn | -44.10 Mn | 14.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 28,000.00 |
| Dec 31, 2023 | 28,000.00 |
| Sep 30, 2023 | 28,000.00 |
| Sep 30, 2023 | 28,000.00 |
| Dec 31, 2021 | 22,000.00 |
| Dec 31, 2021 | 22,000.00 |